You keep seeing two labels on medications: compounded and FDA-approved. They sound alike. They are not the same thing.
Maybe a telehealth ad offered a compounded shot. Maybe your pharmacy stocks a brand you recognize. Now you are not sure what the difference means for you.
This guide explains it in everyday words. You will learn what FDA approval involves, how compounding works, and why the two are not equal. You will also learn what to ask before you decide.
KEY TAKEAWAYS
- FDA-approved medicines pass a full review for safety, effectiveness, and quality before they reach you.
- Compounded preparations are made by licensed pharmacies and are not FDA-approved.
- A generic is FDA-approved and bioequivalent; a compounded preparation is neither.
- Compounded semaglutide is not FDA-approved and not a generic of Wegovy® or Ozempic®.
- As of 2026, semaglutide and tirzepatide are off the FDA shortage list.
What readers want to figure out?
- You want a clear definition of FDA-approved without the legal jargon.
- You want to know what a compounding pharmacy actually does.
- You want to tell a generic apart from a compounded preparation.
- You want to understand where compounded GLP-1 medications stand in 2026.
- You want to know what questions to ask before you decide.
What FDA-Approved really means?
FDA approval is a high bar. A company must prove a medicine is safe and effective for its intended use. The U.S. Food and Drug Administration reviews all of that evidence before approval.
That evidence comes from clinical trials. These are careful studies in people, run in phases. They measure how well a medicine works and what side effects it may cause.
Approval also covers how the medicine is made. FDA-approved drugs are produced under strict rules called Current Good Manufacturing Practice, or CGMP. These rules help ensure the same dose, purity, and quality in every batch.
Wegovy®, Zepbound®, Ozempic®, and Mounjaro® are examples of FDA-approved medicines. Each one cleared this full review for a specific approved use. The label tells you exactly what it was approved to do.
Approval does not stop at launch. The FDA keeps watching an approved medicine for new safety signals. Makers must report problems, and the label can be updated over time.
Here is how a medicine earns FDA approval, step by step.
- A company studies the medicine in the lab and in animals first.
- It then tests the medicine in people through phased clinical trials.
- The FDA reviews the full safety and effectiveness data.
- Inspectors check that the factory meets CGMP quality rules.
- Only then can the medicine be approved and sold for that use.
FDA approval is not a logo. It is years of trials, a full safety review, and factory checks behind every dose.
What Compounding is?
Compounding is the practice of making a medicine to fit a specific need. A licensed pharmacist mixes or alters ingredients for a patient. The result is called a compounded preparation.
Compounding exists for good reasons. A patient may be allergic to a dye in the standard product. A child or older adult may need a liquid instead of a large tablet.
Two kinds of facilities do this work. Knowing the difference helps you ask better questions.
A 503A pharmacy compounds for one patient at a time, based on a prescription. State boards of pharmacy oversee this work. These preparations are not made under the full CGMP factory rules.
A 503B outsourcing facility can make larger batches, sometimes without a patient-specific prescription. The FDA registers and inspects these facilities. They must follow CGMP manufacturing rules.
Here is the part that surprises people. Compounded preparations are not FDA-approved. The FDA does not review their safety, effectiveness, or quality before they are sold.
Because they skip that review, quality can vary. The FDA warns that a compounded drug could be contaminated, or hold too much or too little active drug. Poor quality can lead to serious harm.
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who it serves | One patient with a prescription | Health facilities, larger batches |
| Main oversight | State boards of pharmacy | FDA registration and inspection |
| CGMP factory rules | Not required | Required |
| Makes an FDA-approved product? | No | No |
Generic VS Compounded: Not the same word
People often mix up generic and compounded. The two are very different. Getting this clear can save you a lot of confusion.
A generic medicine is FDA-approved. It must match the brand it copies in dose and form, and it must work the same way in the body. The FDA calls this being bioequivalent.
A generic reaches the market through a review called an Abbreviated New Drug Application. So a generic carries the same FDA backing as the brand. It is simply made by another company.
A compounded preparation is different. It is not FDA-approved, and it is not a generic. No agency has confirmed that it matches any brand-name product.
| FDA-approved brand | FDA-approved generic | Compounded preparation | |
|---|---|---|---|
| FDA-approved? | Yes | Yes | No |
| Reviewed for safety and effectiveness? | Yes | Yes | No |
| Bioequivalence confirmed by FDA? | Not needed (original) | Yes | No |
| Example | Wegovy®, Mounjaro® | Generics of many older drugs | A pharmacy-mixed preparation |
One note keeps this accurate. Popular GLP-1 brands like Wegovy® and Mounjaro® do not have FDA-approved generics yet. So any non-branded version you see is a compounded preparation, not a generic.
A generic is FDA-approved and matches its brand. A compounded preparation is neither approved nor a generic.
FDA-Approved VS Compounded, Side by Side
It helps to see the two side by side. The table below compares an FDA-approved medicine with a compounded preparation. It focuses on how each one is reviewed, tested, and made.
| Feature | FDA-approved medication | Compounded preparation |
|---|---|---|
| FDA review before sale | Yes, full review | No |
| Clinical trials for this product | Yes | No |
| Made under CGMP factory rules | Yes | 503B yes; 503A no |
| Dose and purity checked in every batch | Yes | Not the same way |
| Label with full directions | Yes | May be limited |
| Why it exists | Approved for a specific use | To meet an individual medical need |
The table is not about good versus bad. Compounding can meet a real need for some patients. The point is that the two are not equal, and they are not interchangeable.
The GLP-1 Shortage Story, and Where it stands in 2026
GLP-1 medicines became very popular for weight and blood sugar. Demand outran supply. Starting in 2022, the FDA listed the semaglutide and tirzepatide products as being in shortage.
Those drugs power brands like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.
During a shortage, the law changes what compounders may do. Pharmacies were allowed to compound copies of the shortage drug. This helped patients who could not get the branded product.
That window has since closed. The FDA resolved the tirzepatide shortage on December 19, 2024. It resolved the semaglutide shortage on February 21, 2025.
As of 2026, neither drug is on the FDA shortage list. So broad compounding of copies is generally no longer allowed. A pharmacy may still compound for one patient when a prescriber documents a real clinical need.
Being off the shortage list does not turn a compounded copy into an approved product. Approval status and shortage status are two separate things. Only the FDA review makes a medicine FDA-approved.
You may see ads for compounded semaglutide (not FDA-approved; not a generic of Wegovy® or Ozempic®). The FDA has not reviewed it for safety, effectiveness, or quality. It is not the same as the branded product.
The branded products do carry trial evidence. In the STEP 1 trial, adults on Wegovy® lost about 14.9% of their body weight over 68 weeks (N=1,961, Wilding 2021).
Those trial results apply only to the FDA-approved branded products. They do not transfer to compounded preparations. A compounded version has not been studied the same way.
What to ask before you decide?
You do not need to be an expert to ask smart questions. A few clear questions can tell you a lot. Bring them to a licensed prescriber or pharmacist.
- Is this product FDA-approved, or is it a compounded preparation?
- If it is compounded, what is the medical reason for choosing it?
- Which pharmacy makes it, and is it a 503A or 503B facility?
- What exact ingredients and dose are in the preparation?
- How will follow-up, side effects, and problems be handled?
- How do I report a bad reaction to the FDA if one happens?
Write the answers down. Compare them calmly, without pressure. A good provider will welcome these questions, not dodge them.
The Bottom Line
Compounded and FDA-approved are not the same thing. FDA-approved medicines pass a full review for safety, effectiveness, and quality, while compounded preparations skip that review. A generic is FDA-approved and bioequivalent, but a compounded preparation is neither.
FREQUENTLY ASKED QUESTIONS
No, compounded preparations are not FDA-approved. The FDA does not review their safety, effectiveness, or quality before they are sold. Licensed pharmacies make them to meet a specific patient need. They can serve a real purpose, but they do not carry the same federal review and testing as an FDA-approved medicine.
No, a generic is FDA-approved and must match the brand it copies, working the same way in the body. A compounded preparation is neither approved nor a generic. No agency has confirmed that it matches a brand-name product. The two words describe very different things, so it helps to keep them separate.
No, compounded semaglutide is not FDA-approved, and it is not a generic of Wegovy® or Ozempic®. The FDA has not reviewed it for safety, effectiveness, or quality. Trial results for the branded products do not transfer to compounded preparations. If a provider offers it, ask why it was chosen for you.
Compounding fills gaps that standard products cannot. A patient may be allergic to a dye or filler in the approved medicine. A child or older adult may need a liquid instead of a tablet, or a prescriber may need a strength that is not sold. In these cases, a licensed pharmacy can prepare a custom version.
No, the FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. As of 2026, neither appears on the FDA shortage list. Because the shortage has ended, broad compounding of copies is generally no longer allowed. Limited compounding for an individual patient may still occur when a prescriber documents a clinical need.
A 503A pharmacy compounds for one patient at a time, based on a prescription, and is overseen by state boards. A 503B outsourcing facility can make larger batches, is registered and inspected by the FDA, and must follow CGMP manufacturing rules. Neither one makes FDA-approved products. Both must still meet safety and quality laws.
Ask directly, and check the label. FDA-approved products list an approved use and full directions, and you can look them up in the FDA database. If a product is compounded, the provider or pharmacy should tell you. When in doubt, ask whether the exact product went through FDA review, not just the active drug.
It depends, because compounding can meet a real need but does not carry FDA review. If a preparation is contaminated or holds too much or too little active drug, it can cause harm. Labels may also lack full directions. Ask about the pharmacy, the ingredients, and follow-up, and report any bad reaction to the FDA.
Go deeper
Best GLP-1 providers, compared
Ready to compare your options? See how leading GLP-1 telehealth services line up on approval status, pharmacy type, and follow-up care.
→ See the GLP-1 provider comparison
SOURCES
- US Food and Drug Administration. Understanding the Risks of Compounded Drugs. 2026. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- US Food and Drug Administration. FD&C Act Provisions that Apply to Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
- US Food and Drug Administration. Generic Drugs: Questions & Answers. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers
- US Food and Drug Administration. Facts About the Current Good Manufacturing Practice (CGMP). https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp
- US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Last updated: 2026-07-09 · Editorially reviewed by the Peptides.io team
Comments